Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

ByThe Short Paper

This study explored a treatment combination (obinutuzumab, ibrutinib, and venetoclax) for a specific type of leukemia (chronic lymphocytic leukemia with del(17p) and/or TP53 mutation) in previously untreated patients. The treatment involved several cycles and aimed to achieve complete remission.

The results showed that 58.5% of patients achieved complete remission, and after around 3 years, the progression-free survival rate was 79.9%, with an overall survival rate of 92.6%. Some patients experienced side effects like neutropenia, infections, and cardiovascular issues, but these generally decreased over time.

In summary, this treatment regimen appears promising for high-risk chronic lymphocytic leukemia patients with manageable side effects.

Similar Posts

Extrapulmonary manifestations of COVID-19

ByThe Short Paper

Article There are many organs that COVID-19 may target due to a common receptor that COVID-19 uses to enter, ACE2. This can cause issues in cardiac, renal, endocrine, and ocular systems and more. TL;DR COVID-19 has been shown to cause more than respiratory issues, many organs are affected due to a common receptor on all of…

SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity

ByThe Short Paper

Article 967 subjects were tested for IgG antibodies against COVID-19. They multiple subgroups of suspected cases, healthy donors, patients with rheumatic disease, and patients positive for polymerase chain reaction. They found PCR and IgG were in agreement in 83% of samples.  The levels of IgG and IgM levels were measured and found to not associate with…

Food Insecurity Is Associated With Higher Health Care Use And Costs Among Canadian Adults

ByThe Short Paper

Article The researchers looked at Canadian hospital and healthcare expenditure records. They looked at specific characteristics of patients specifically acute care hospitalization, same-day surgery, and acute care costs among Canadian adults. Patients who were more food insecure were more likely to be admitted for acute care as well as having surgery. They  found that patients…

Choosing Your Search Engine on Android: How Auctions Matter

ByThe Short Paper

Choice Screen Auctions In Europe, you can now choose your search engine on Android instead of using Google’s automatically. However, a small change in how these choices are made, either based on how often they appear or how often they are installed, can affect which search engines win and how much of the market they…

Transforming the Iron and Steel Industry for Net-Zero Emissions

ByThe Short Paper

Global iron and steel plant CO2 emissions and carbon-neutrality pathways The iron and steel industry, a major source of CO2 emissions, is crucial for addressing climate change. A study mapped emissions and technologies for over 4,800 individual plants, creating tailored plans to reduce emissions. Retrofitting these plants with low-carbon tech during their operational years can limit…

Boosting Immune Memory for Enhanced Cancer Therapy

ByThe Short Paper

Reductive carboxylation epigenetically instructs T cell differentiation Immune cells called CD8+ T cells play a crucial role in protecting the body from diseases like cancer by undergoing metabolic changes when activated. Researchers found that one specific metabolic process involving a mitochondrial enzyme called IDH2 affects the development of memory CD8+ T cells. Inhibiting IDH2 during…